Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $108.5 million.

  • Apellis Pharmaceuticals' Cash from Operations rose 21812.53% to $108.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.9 million, marking a year-over-year increase of 13845.08%. This contributed to the annual value of -$87.9 million for FY2024, which is 8522.6% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Cash from Operations stood at $108.5 million for Q3 2025, which was up 21812.53% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Cash from Operations registered a high of $108.5 million during Q3 2025, and its lowest value of -$177.6 million during Q1 2023.
  • Moreover, its 5-year median value for Cash from Operations was -$112.5 million (2021), whereas its average is -$89.5 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Cash from Operations crashed by 17923.64% in 2021 and then skyrocketed by 21812.53% in 2025.
  • Apellis Pharmaceuticals' Cash from Operations (Quarter) stood at -$112.5 million in 2021, then dropped by 25.11% to -$140.7 million in 2022, then soared by 30.46% to -$97.9 million in 2023, then surged by 119.78% to $19.4 million in 2024, then soared by 460.27% to $108.5 million in 2025.
  • Its Cash from Operations stands at $108.5 million for Q3 2025, versus $4.4 million for Q2 2025 and -$53.4 million for Q1 2025.